多西紫杉醇+顺铂方案联合康艾注射液治疗晚期胃癌的近期疗效及安全性

Recent efficacy and safety evaluation of docetaxel + cisplatin combined Kang'ai injection for advanced gastric cancer

目的探讨多西紫杉醇+顺铂方案联合康艾注射液治疗晚期胃癌的近期疗效及安全性。方法以78例晚期胃癌患者为研究对象,采用随机数字法分为多西紫杉醇+顺铂方案联合康艾注射液组(D+C+K组)40例和多西紫杉醇+顺铂方案组(D+C组)38例,观察两组临床治疗效果及相关症状发生情况。结果治疗前,D+C+K组与D+C组患者的白细胞计数没有统计学差异(P>0.05);治疗后与治疗前比较两组白细胞计数均有较大幅度的降低(P<0.05);但相对于D+C组,治疗后D+C+K组白细胞计数有了较大幅度的下降(P<0.05)。治疗前,D+C+K组与D+C组的CD4,CD8,CD4/CD8比值无显著性差异;而治疗后,D+C+K组与治疗前相比差异不明显(P>0.05),D+C组的CD4,CD8,CD4/CD8比值与治疗前相比却有了较大幅度的下降(P<0.05)。D+C+K组临床症状改善率和健康状况变化(KPS)提高率分别为92.5%(37/40)和82.5%(33/40),明显高于D+C组〔50.0%(19/38),47.4%(18/38)〕(P<0.05)。结论多西紫杉醇+顺铂方案联合康艾注射液治疗晚期胃癌近期效果较好,可以缓解由于化疗药物引起的白细胞计数降低,从而改善患者生活质量并提高安全性。

Objective To investigate the effect of docetaxel + cisplatin combined Kang’ai injection for advanced gastric cancer and safety evaluation. Methods 78 patients were divided into Kang’ai injection combined docetaxel + cisplatin group( D + C + K group) 40 patients and docetaxel + cisplatin group( D + C group) 38 patients. Results The leukopenia cells were not significantly different before treatment in both D + C and D + C + K groups( P > 0. 05),the leukopenia cells after treatment in both D + C and D + C + K groups were reduced significantly compared to those before treatment( P < 0. 05),and the reduction of D + C + K group was less than that of D + C group. The values of CD4,CD8,CD4 / CD8 were not obviously different in D + C + K group before treatment. And no significantly difference was detected in D + C + K group after treatment,while the values of CD4,CD8,CD4 / CD8 in D + C group were significantly reduced. However,there was difference in D + C group( P < 0. 05). The patients( 37 /40) in clinical symptoms were improved whereas patients( 33 /40) were enhanced in KPS in D + C + K group. The improvement rate for clinical symptoms and enhancement rate for KPS in D + C + K group were increased 92.5%( 37 /40),82. 5%( 33 /40),respectively,which were higher than those of D + C group( P < 0. 05). Conclusions Kang’ai injection combined docetaxel + cisplatin could significantly improve the quality of life in patients with an increasing high security.